

Access DB# 133450

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabaha Qazi Examiner #: 74141 Date: 9/23/04
Art Unit: 74141 Phone Number: 20622 Serial Number: 10/616,333
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. ME

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Oxazole for Treating Cytokine-Mediated Diseases

Inventors (please provide full names): Adams et al.

Earliest Priority Filing Date: 11/8/1994 - (5/8/96) ✓

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search for Oxazole compds of cl 17 formula (1) where one of the R₁ or R₂ can be pyrimidine.

Please search for a specific compd of cl 21

Please see att sched sheet

Thank you

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Jan</u>	NA Sequence (#) _____	STN <u>✓</u>
Searcher Phone #: <u>20504</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>✓</u>	Questel/Orbit _____
Date Searcher Picked Up: <u>9/29</u>	Bibliographic _____	Dr.Link _____
Date Completed: <u>9/29</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Searcher Prep Time: <u>10</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>+25</u>	Other _____	Other (specify) _____

=> fil reg

FILE 'REGISTRY' ENTERED AT 13:22:35 ON 29 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2004 HIGHEST RN 753424-73-6
DICTIONARY FILE UPDATES: 28 SEP 2004 HIGHEST RN 753424-73-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d l16 ide can

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 166895-13-2 REGISTRY
CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX
NAME)
FS 3D CONCORD
MF C13 H9 F N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 123:152881

=> d his

(FILE 'HOME' ENTERED AT 13:16:46 ON 29 SEP 2004)

SET COST OFF

FILE 'HCAPLUS' ENTERED AT 13:16:57 ON 29 SEP 2004

L1 1 S US20040106793/PN OR (WO94-US13067 OR US96-640966# OR US2003-6
E ADAMS J/AU
L2 205 S E3,E33,E34
E ADAMES JERAU
E ADAMES JER/AU
E ADAMES JER/AU
E ADAMS JER/AU
L3 145 S E7,E11,E13
E GALLAGHER T/AU
L4 460 S E3,E7,E8
E GALLAGHER TIM/AU
L5 182 S E4,E8,E9
E BOEHM J/AU
L6 119 S E3,E4
L7 61 S E18-E21
E BOHM J/AU
L8 124 S E3
E THOMPSON S/AU
L9 169 S E3,E21
E THOMPSON SUE/AU
L10 1 S E3
L11 18 S E12,E18-E20
SEL RN L1

FILE 'REGISTRY' ENTERED AT 13:20:27 ON 29 SEP 2004

L12 50 S E1-E50
L13 11 S L12 AND 46.150.18/RID AND NCOC2/ES AND 3/NR
L14 1 S L13 NOT NC5/ES
E C13H9FN40/MF
L15 1 S E3 AND (C6 AND NCNC3 AND NCOC2)/ES
L16 1 S L14,L15
SEL RN
L17 0 S E1/CRN

FILE 'HCAOLD' ENTERED AT 13:21:57 ON 29 SEP 2004

L18 0 S L16

FILE 'HCAPLUS' ENTERED AT 13:22:00 ON 29 SEP 2004

L19 1 S L16
L20 1 S L19 AND L1-L11

FILE 'USPATFULL, USPAT2' ENTERED AT 13:22:13 ON 29 SEP 2004

L21 3 S L16

FILE 'REGISTRY' ENTERED AT 13:22:35 ON 29 SEP 2004

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 13:22:41 ON 29 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2004 VOL 141 ISS 14
FILE LAST UPDATED: 28 Sep 2004 (20040928/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 120 all hitstr

L20 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:756382 HCAPLUS
DN 123:152881
ED Entered STN: 25 Aug 1995
TI Oxazoles for treating cytokine-mediated diseases
IN Adams, Jerry Leroy; Gallagher, Timothy Francis;
Boehm, Jeffrey Charles; Thompson, Susan Mary
PA SmithKline Beecham Corp., USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-44
ICS A61K031-505; C07D413-04
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 28

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9513067	A1	19950518	WO 1994-US13067	19941108 <--
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 727998	A1	19960828	EP 1995-902538	19941108 <--
	EP 727998	B1	20040121		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	JP 09505055	T2	19970520	JP 1994-514047	19941108 <--
	EP 1306377	A2	20030502	EP 2003-75256	19941108
	EP 1306377	A3	20030507		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	US 6288062	B1	20010911	US 1999-467164	19991220 <--
	US 2002169173	A1	20021114	US 2001-769096	20010125 <--
	US 2004106793	A1	20040603	US 2003-616333	20030709 <--
PRAI	US 1993-148705	A	19931108		
	EP 1995-902538	A3	19941108		
	WO 1994-US13067	W	19941108	<--	
	US 1996-640966	B1	19960508	<--	
	US 1999-467164	A	19991220		
	US 2001-769096	B1	20010125		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9513067	ICM	A61K031-44
	ICS	A61K031-505; C07D413-04
EP 1306377	ECLA	C07D413/04
US 2004106793	ECLA	C07D413/04; C07D413/04

OS MARPAT 123:152881

AB A method of inhibiting cytokines and treating cytokine-mediated diseases, comprises administration of the novel oxazole compds. The cytokine-mediated diseases include asthma, adult respiratory distress syndrome, stroke, bone resorption diseases, arthritic joint conditions, and other inflammatory diseases. For example, 14 compds. were prepared,

such as 5-(3-methoxyphenyl)-2-methyl-4-(4-pyridyl)oxazole and cytokine-inhibiting effects of the compds. were in vitro tested by monitoring interleukin 1, tumor necrosis factor, and interleukin 8.

ST oxazole deriv prepn cytokine mediated disease

IT Inflammation inhibitors
(preparation of oxazoles for treating cytokine-mediated diseases)

IT Lymphokines and Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of oxazoles for treating cytokine-mediated diseases)

IT Bone, disease
(resorption; preparation of oxazoles for treating cytokine-mediated diseases)

IT Respiratory distress syndrome
(adult, preparation of oxazoles for treating cytokine-mediated diseases)

IT Inflammation inhibitors
(antiarthritics, preparation of oxazoles for treating cytokine-mediated diseases)

IT Bronchodilators
(antiasthmatics, preparation of oxazoles for treating cytokine-mediated diseases)

IT Lymphokines and Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(interleukin 1, preparation of oxazoles for treating cytokine-mediated diseases)

IT Brain, disease
(stroke, preparation of oxazoles for treating cytokine-mediated diseases)

IT Lymphokines and Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tumor necrosis factor, preparation of oxazoles for treating cytokine-mediated diseases)

IT 75-12-7, Formamide, reactions 127-09-3, Sodium acetate 420-04-2, Cyanamide 459-57-4, p-Fluorobenzaldehyde 532-32-1, Sodium benzoate 587-04-2, 3-Chlorobenzaldehyde 635-39-2, Guanine hydrochloride 872-85-5, Pyridine-4-carboxaldehyde 4637-24-5 5470-11-1, Hydroxylamine hydrochloride 5807-14-7 6287-38-3, 3,4-Dichlorobenzaldehyde 6342-56-9, Pyruvic aldehyde dimethylacetal 6576-05-2 6921-34-2, Benzyl magnesium chloride 14254-57-0, Isonicotinoyl chloride 26445-03-4, Thiocresol 36768-62-4 63875-01-4, 2-Methylpyridine-4-carboxaldehyde 165807-06-7 166895-17-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazoles for treating cytokine-mediated diseases)


IT 1017-24-9P 2116-61-2P 113397-59-4P 165806-85-9P 165807-05-6P 166895-14-3P 166895-15-4P 166895-16-5P 166895-18-7P 166895-19-8P 166895-20-1P 166895-21-2P 166895-22-3P 166895-23-4P 166895-24-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazoles for treating cytokine-mediated diseases)

IT 166895-00-7P 166895-01-8P 166895-02-9P 166895-03-0P 166895-04-1P 166895-05-2P 166895-06-3P 166895-07-4P 166895-08-5P 166895-09-6P 166895-10-9P 166895-11-0P 166895-12-1P 166895-13-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazoles for treating cytokine-mediated diseases)

IT 166895-13-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazoles for treating cytokine-mediated diseases)

RN 166895-13-2 HCAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



=> fil uspatall

FILE 'USPATFULL' ENTERED AT 13:22:47 ON 29 SEP 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:22:47 ON 29 SEP 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr tot 121

L21 ANSWER 1 OF 3 USPATFULL on STN
 AN 2004:139617 USPATFULL
 TI Oxazoles for treating cytokine mediated diseases
 IN Adams, Jerry Leroy, Wayne, PA, UNITED STATES
 Gallagher, Timothy Francis, Harleysville, PA, UNITED STATES
 Boehm, Jeffrey Charles, King of Prussia, PA, UNITED STATES
 Thompson, Susan Mary, Phoenixville, PA, UNITED STATES
 PA SmithKline Beecham Corporation (U.S. corporation)
 PI US 2004106793 A1 20040603
 AI US 2003-616333 A1 20030709 (10)
 RLI Continuation of Ser. No. US 2001-769096, filed on 25 Jan 2001, ABANDONED
 Division of Ser. No. US 1999-467164, filed on 20 Dec 1999, GRANTED, Pat.
 No. US 6288062 Continuation of Ser. No. US 1996-640966, filed on 8 May
 1996, ABANDONED A 371 of International Ser. No. WO 1994-US13067, filed
 on 8 Nov 1994, PENDING Continuation-in-part of Ser. No. US 1993-148705,
 filed on 8 Nov 1993, ABANDONED
 DT Utility
 FS APPLICATION
 LREP GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box
 1539, King of Prussia, PA, 19406-0939
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1848
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to the novel oxazole compounds of Formula (I) and
 novel pharmaceutical compositions comprising a compound of Formula (I)
 and a pharmaceutically acceptable diluent or carrier.

This invention also relates to a method of inhibiting cytokines and the
 treatment of cytokine mediated diseases, in mammals, thereby by
 administration of an effective amount of a compound according to Formula
 (I).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 166895-13-2P

(preparation of oxazoles for treating cytokine-mediated diseases)

RN 166895-13-2 USPATFULL

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 2 OF 3 USPATFULL on STN
 AN 2002:301628 USPATFULL
 TI Oxazoles for treating cytokine mediated diseases
 IN Adams, Jerry Leroy, Wayne, PA, UNITED STATES
 Gallagher, Timothy Francis, Harleysville, PA, UNITED STATES
 Boehm, Jeffrey Charles, King of Prussia, PA, UNITED STATES
 Thompson, Susan Mary, Phoenixville, PA, UNITED STATES
 PA SmithKline Beecham Corporation (U.S. corporation)
 PI US 2002169173 A1 20021114
 AI US 2001-769096 A1 20010125 (9)
 RLI Continuation of Ser. No. US 1996-640966, filed on 8 May 1996, ABANDONED
 Continuation of Ser. No. WO 1994-US13067, filed on 8 Nov 1994, UNKNOWN
 PRAI US 1999-467164 19991220 (09)
 DT Utility
 FS APPLICATION
 LREP SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US,
 UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1848
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to the novel oxazole compounds of Formula (I) and
 novel pharmaceutical compositions comprising a compound of Formula (I)
 and a pharmaceutically acceptable diluent or carrier.

This invention also relates to a method of inhibiting cytokines and the
 treatment of cytokine mediated diseases, in mammals, thereby by
 administration of an effective amount of a compound according to Formula
 (I).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 166895-13-2P

(preparation of oxazoles for treating cytokine-mediated diseases)

RN 166895-13-2 USPATFULL

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 3 OF 3 USPATFULL on STN
 AN 2001:152959 USPATFULL
 TI Oxazoles for treating cytokine mediated diseases
 IN Adams, Jerry Leroy, Wayne, PA, United States
 Gallagher, Timothy Francis, Harleysville, PA, United States
 Boehm, Jeffrey Charles, King of Prussia, PA, United States
 Thompson, Susan Mary, Phoenixville, PA, United States
 PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
 PI US 6288062 B1 20010911
 AI US 1999-467164 19991220 (9)
 RLI Continuation of Ser. No. US 640966, now abandoned Continuation-in-part of Ser. No. US 1993-148705, filed on 8 Nov 1993
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Qazi, Sabiha
 LREP Dinner, Dara L., Venetianer, Stephen, Kinzig, Charles M.
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1840
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to the novel oxazole compounds of Formula (I) and novel pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of inhibiting cytokines and the treatment of cytokine mediated diseases, in mammals, thereby by administration of an effective amount of a compound according to Formula (I).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 166895-13-2P

(preparation of oxazoles for treating cytokine-mediated diseases)

RN 166895-13-2 USPATFULL

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



=> => fil reg

FILE 'REGISTRY' ENTERED AT 13:37:40 ON 29 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2004 HIGHEST RN 753424-73-6
DICTIONARY FILE UPDATES: 28 SEP 2004 HIGHEST RN 753424-73-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004




Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que l32

L12 50 SEA FILE=REGISTRY ABB=ON PLU=ON (1017-24-9/BI OR 113397-59-4/
BI OR 127-09-3/BI OR 14254-57-0/BI OR 165806-85-9/BI OR
165807-05-6/BI OR 165807-06-7/BI OR 166895-00-7/BI OR 166895-01
-8/BI OR 166895-02-9/BI OR 166895-03-0/BI OR 166895-04-1/BI OR
166895-05-2/BI OR 166895-06-3/BI OR 166895-07-4/BI OR 166895-08
-5/BI OR 166895-09-6/BI OR 166895-10-9/BI OR 166895-11-0/BI OR
166895-12-1/BI OR 166895-13-2/BI OR 166895-14-3/BI OR 166895-15
-4/BI OR 166895-16-5/BI OR 166895-17-6/BI OR 166895-18-7/BI OR
166895-19-8/BI OR 166895-20-1/BI OR 166895-21-2/BI OR 166895-22
-3/BI OR 166895-23-4/BI OR 166895-24-5/BI OR 2116-61-2/BI OR
26445-03-4/BI OR 36768-62-4/BI OR 420-04-2/BI OR 459-57-4/BI
OR 4637-24-5/BI OR 532-32-1/BI OR 5470-11-1/BI OR 5807-14-7/BI
OR 587-04-2/BI OR 6287-38-3/BI OR 6342-56-9/BI OR 635-39-2/BI
OR 63875-01-4/BI OR 6576-05-2/BI OR 6921-34-2/BI OR 75-12-7/BI
OR 872-85-5/BI)
L13 11 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND 46.150.18/RID AND
NCOC2/ES AND 3/NR
L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON L13 NOT NC5/ES
L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON C13H9FN4O/MF AND (C6 AND
NCNC3 AND NCOC2)/ES
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON (L14 OR L15)
L29 STR



VAR G1=6/15

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 3 7 14

NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

L31 45 SEA FILE=REGISTRY SSS FUL L29




L32 44 SEA FILE=REGISTRY ABB=ON PLU=ON L31 NOT L16

=> d sta que 149

L22 2454 SEA FILE=REGISTRY ABB=ON PLU=ON (NCOC2 AND NCNC3)/ES AND

NR>=3

L29 STR



VAR G1=6/15

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RSPEC 3 7 14

NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

L31 45 SEA FILE=REGISTRY SSS FUL L29
 L46 STR



VAR G1=6/15

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY AT 22

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E4 C E2 N AT 22

GRAPH ATTRIBUTES:

RSPEC 3 14

NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L48 73 SEA FILE=REGISTRY SUB=L22 SSS FUL L46

L49 28 SEA FILE=REGISTRY ABB=ON PLU=ON L48 NOT L31

=> d his

(FILE 'HOME' ENTERED AT 13:16:46 ON 29 SEP 2004)

SET COST OFF

FILE 'HCAPLUS' ENTERED AT 13:16:57 ON 29 SEP 2004

L1 1 S US20040106793/PN OR (WO94-US13067 OR US96-640966# OR US2003-6
 E ADAMS J/AU
 L2 205 S E3,E33,E34
 E ADAMES JERAU
 E ADAMES JER/AU
 E ADAMES JER/AU
 E ADAMS JER/AU
 L3 145 S E7,E11,E13
 E GALLAGHER T/AU
 L4 460 S E3,E7,E8
 E GALLAGHER TIM/AU
 L5 182 S E4,E8,E9
 E BOEHM J/AU
 L6 119 S E3,E4
 L7 61 S E18-E21
 E BOHM J/AU
 L8 124 S E3
 E THOMPSON S/AU
 L9 169 S E3,E21
 E THOMPSON SUE/AU
 L10 1 S E3
 L11 18 S E12,E18-E20
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 13:20:27 ON 29 SEP 2004

L12 50 S E1-E50
 L13 11 S L12 AND 46.150.18/RID AND NCOC2/ES AND 3/NR
 L14 1 S L13 NOT NC5/ES

E C13H9FN4O/MF
L15 1 S E3 AND (C6 AND NCNC3 AND NCOC2)/ES
L16 1 S L14,L15
SEL RN
L17 0 S E1/CRN

FILE 'HCAOLD' ENTERED AT 13:21:57 ON 29 SEP 2004
L18 0 S L16

FILE 'HCAPLUS' ENTERED AT 13:22:00 ON 29 SEP 2004
L19 1 S L16
L20 1 S L19 AND L1-L11

FILE 'USPATFULL, USPAT2' ENTERED AT 13:22:13 ON 29 SEP 2004
L21 3 S L16

FILE 'REGISTRY' ENTERED AT 13:22:35 ON 29 SEP 2004

FILE 'HCAPLUS' ENTERED AT 13:22:41 ON 29 SEP 2004

FILE 'USPATFULL, USPAT2' ENTERED AT 13:22:47 ON 29 SEP 2004

FILE 'REGISTRY' ENTERED AT 13:23:43 ON 29 SEP 2004
L22 2454 S (NCOC2 AND NCNC3)/ES AND NR>=3
L23 STR
L24 5 S L23 SAM SUB=L22
L25 2191 S L22 AND 46.195.39/RID
L26 623 S L25 AND 16.239.9/RID
L27 STR L23
L28 3 S L27
L29 STR L27
L30 3 S L29
L31 45 S L29 FUL
SAV TEMP L31 QAZI616/A
L32 44 S L31 NOT L16
L33 33 S L31 AND 46.195.39/RID
L34 33 S L33 AND 16.239.9/RID
L35 12 S L32 NOT L34
L36 1 S L34 AND L16
L37 32 S L34 NOT L36

FILE 'HCAOLD' ENTERED AT 13:30:57 ON 29 SEP 2004
L38 0 S L37
L39 0 S L35

FILE 'HCAPLUS' ENTERED AT 13:31:02 ON 29 SEP 2004
L40 3 S L37
L41 1 S L35
L42 4 S L40,L41
L43 0 S L42 AND (PY<=1996 OR PRY<=1996 OR AY<=1996)

FILE 'USPATFULL, USPAT2' ENTERED AT 13:34:21 ON 29 SEP 2004
L44 3 S L37 OR L35
L45 0 S L44 AND (PY<=1996 OR PRY<=1996 OR AY<=1996)

FILE 'REGISTRY' ENTERED AT 13:34:57 ON 29 SEP 2004
L46 STR L29
L47 3 S L46 SAM SUB=L22
L48 73 S L46 FUL SUB=L22
SAV L48 TEMP QAZI616A/A
L49 28 S L48 NOT L31
L50 0 S L49 AND 46.195.39/RID

FILE 'HCAPLUS' ENTERED AT 13:36:38 ON 29 SEP 2004

L51 3 S L49

L52 1 S L51 AND (PY<=1996 OR PRY<=1996 OR AY<=1996)

FILE 'REGISTRY' ENTERED AT 13:37:40 ON 29 SEP 2004

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 13:38:15 ON 29 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2004 VOL 141 ISS 14

FILE LAST UPDATED: 28 Sep 2004 (20040928/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l52 all hitstr

L52 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:92475 HCAPLUS

DN 122:31451

ED Entered STN: 08 Nov 1994

TI Heterocyclization based on 1-[benzoyl(benzoylamino)methyl]uracil

AU Khutova, B. M.; Klyuchko, S. V.; Prikazchikova, L. P.; Drach, B. S.

CS Inst. Bioorg. Khim. Neftekhim., Kiev, Ukraine

SO Ukrainskii Khimicheskii Zhurnal (Russian Edition) (1993),
59(10), 1067-70

CODEN: UKZHAU; ISSN: 0041-6045

DT Journal

LA Russian

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

AB Reaction of 1-[benzoyl(benzoylamino)methyl]uracil with thionyl chloride or phosphorus pentasulfide led to 1-(4-oxazolyl)uracils and 1-(4-thiazolyl)-4-thiouracils. The structures of the products were proved by PMR spectroscopy.

ST uracil benzamidobenzoylmethyl cyclization; cyclization
benzamidobenzoylmethyluracil; oxazolyluracil; thiazolylthiouracil;
thiouracil thiazolyl

IT Ring closure and formation

(in [benzoyl(benzoylamino)methyl]uracil reactions with thionyl chloride
and phosphorus pentasulfide)


IT 159830-46-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with amines)


IT 159830-53-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with aniline)


- IT **159830-45-2P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction with phosphorus pentasulfide)
- IT 159830-47-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction with thionyl chloride)
- IT **159830-48-5P 159830-49-6P 159830-50-9P**
 159830-51-0P 159830-52-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
- IT 1314-80-3, Phosphorus pentasulfide 7719-09-7, Thionyl chloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction with [benzoyl(benzoylamino)methyl]uracil)
- IT 62-53-3, Aniline, reactions 110-91-8, Morpholine, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction with dichlorooxazolyluracil derivative)
- IT 130925-51-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction with phosphorus pentasulfide and with thionyl chloride)
- IT **159830-46-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction with amines)
- RN 159830-46-3 HCAPLUS
 CN 2(1H)-Pyrimidinone, 4,5-dichloro-1-(2,5-diphenyl-4-oxazolyl)- (9CI) (CA
 INDEX NAME)



- IT **159830-45-2P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction with phosphorus pentasulfide)
- RN 159830-45-2 HCAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-(2,5-diphenyl-4-oxazolyl)- (9CI)
 (CA INDEX NAME)




- IT **159830-48-5P 159830-49-6P 159830-50-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
- RN 159830-48-5 HCAPLUS
 CN 2(1H)-Pyrimidinone, 5-chloro-1-(2,5-diphenyl-4-oxazolyl)-3,4-dihydro-4-
 thio- (9CI) (CA INDEX NAME)




RN 159830-49-6 HCAPLUS

CN 2(1H)-Pyrimidinone, 5-chloro-1-(2,5-diphenyl-4-oxazolyl)-4-(phenylamino)-
(9CI) (CA INDEX NAME)



RN 159830-50-9 HCAPLUS

CN 2(1H)-Pyrimidinone, 5-chloro-1-(2,5-diphenyl-4-oxazolyl)-4-(4-morpholinyl)-
(9CI) (CA INDEX NAME)



=>